Standard treatment of Ph+ CML in 2010: How, when and where not to use what BCR/ABL1 kinase inhibitor?

European Journal of Clinical Investigation

Volumn 40, Issue 10, 2010, Pages 918-931

  Valent, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

BCR ABL1 mutations; CML; dasatinib; imatinib; nilotinib

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; 2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 7 [4 [2 (2 METHOXYETHYLAMINO)ETHOXY]PHENYL] 5 (4 METHOXYPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANTILEUKEMIC AGENT; AP 23848; AP 24534; AS 703569; BAFETINIB; BCR ABL PROTEIN; BILIRUBIN; BOSUTINIB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; CYTARABINE; DANUSERTIB; DASATINIB; DCC 2036; IMATINIB; KW 2449; MUTANT PROTEIN; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; NILOTINIB; ON 01910; PANCREAS ENZYME; PHOSPHOTRANSFERASE INHIBITOR; SARACATINIB; SGX 393; SGX 70393; SORAFENIB; TG 100598; TG 101114; TOZASERTIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VE 465; XL 228;

BCR ABL1 GENE; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER PATIENT; CANCER RESISTANCE; CANCER STEM CELL; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CYTOPENIA; DRUG TOLERABILITY; FOLLICULITIS; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKEMIA RELAPSE; LUNG TOXICITY; MEDICAL DECISION MAKING; ONCOGENE; PATIENT COMPLIANCE; PERICARDIAL EFFUSION; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; REVIEW; SEPTICEMIA; SIDE EFFECT; TREATMENT INDICATION; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 77956502134     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02328.x     Document Type: Review

References (146)

1. Nowell PC, Hungerford DA. A minute chromosome in human granulocytic leukemia. Science 1960 132 : 1497.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973 243 : 290 293.
3. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1982 300 : 765 767.
4. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990 247 : 824 830.
5. Wetzler M, Talpaz M, Van Etten RA, Hirsh-Ginsberg C, Beran M, Kurzrock R. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation. J Clin Invest 1993 92 : 1925 1939.
6. Cortes J, Kantarjian H. Advanced-phase chronic myeloid leukemia. Semin Hematol 2003 40 : 79 86.
7. Giles FJ, Cortes JE, Kantarjian HM, O'Brien SM. Accelerated and blastic phases of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004 18 : 753 774.
8. Cortes JE, Talpaz M, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006 106 : 1306 1315.
9. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986 314 : 202 207.
10. Silberman G, Crosse MG, Peterson EA, Weston RC, Horowitz MM, Appelbaum FR et al. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med 1994 331 : 1063 1067.
11. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998 352 : 1087 1092.
12. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002 8 : 935 942.
13. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002 346 : 645 652.
14. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003 348 : 994 1004. (Pubitemid 36302244)
15. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003 349 : 1423 1432. (Pubitemid 37211057)
16. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001 344 : 1038 1042.
17. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 99 : 1928 1937. (Pubitemid 34525471)
18. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002 99 : 3530 3539. (Pubitemid 34534519)
19. Barnes DJ, Melo JV. Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006 5 : 2862 2866.
20. Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A et al. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007 21 : 926 935.
21. Valent P. Emerging stem cell concepts for imatinib-resistant chronic myeloid leukaemia: implications for the biology, management, and therapy of the disease. Br J Haematol 2008 142 : 361 378.
22. Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007 109 : 58 60.
23. Darkow T, Henk HJ, Thomas SK, Feng W, Baladi JF, Goldberg GA et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007 25 : 481 496.
24. Valent P. Targeting of leukemia-initiating cells to develop curative drug therapies: straightforward but nontrivial concept. Curr Cancer Drug Targets 2010 in press.
25. Weisberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000 95 : 3498 3505.
26. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002 2 : 117 125.
27. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002 99 : 3472 3475.
28. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002 359 : 487 491.
29. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006 145 : 913 923. (Pubitemid 351639967)
30. Mahon FX, Belloc F, Lagarde V, Chollet C, Moreau-Gaudry F, Reiffers J et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003 101 : 2368 2373.
31. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004 104 : 3739 3745.
32. Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, von Bonin M et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004 18 : 401 408.
33. Villuendas R, Steegmann JL, Pollán M, Tracey L, Granda A, Fernández-Ruiz E et al. Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach. Leukemia 2006 20 : 1047 1054.
34. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 305 : 399 401.
35. Weisberg E, Manley PW, Breitenstein W, Brüggen J, Cowan-Jacob SW, Ray A et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005 7 : 129 141.
36. Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K et al. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007 109 : 306 314.
37. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006 66 : 11314 11322.
38. Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. New tyrosine kinase inhibitors in chronic myeloid leukemia. Haematologica 2005 90 : 534 541. (Pubitemid 40592897)
39. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007 7 : 345 356.
40. Quintás-Cardama A, Kantarjian H, Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007 6 : 834 848.
41. Hernández JM, González-Sarmiento R, Martin C, González M, Sánchez I, Corral J et al. Immunophenotypic, genomic and clinical characteristics of blast crisis of chronic myelogenous leukaemia. Br J Haematol 1991 79 : 408 414.
42. Haung ML, Ho CH. Diagnostic value of an automatic hematology analyzer in patients with hematologic disorders. Adv Ther 1998 15 : 137 141.
43. Ducrest S, Meier F, Tschopp C, Pavlovic R, Dahinden CA. Flowcytometric analysis of basophil counts in human blood and inaccuracy of hematology analyzers. Allergy 2005 60 : 1446 1450.
44. Lesesve JF, Benbih M, Lecompte T. Accurate basophils counting: not an easy goal Clin Lab Haematol 2005 27 : 143 144.
45. Bühring HJ, Simmons PJ, Pudney M, Müller R, Jarrossay D, van Agthoven A et al. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors. Blood 1999 94 : 2343 2356.
46. Agis H, Krauth MT, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 2006 125 : 273 281.
47. Agis H, Krauth MT, Mosberger I, Müllauer L, Simonitsch-Klupp I, Schwartz LB et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol 2006 59 : 396 402.
48. Agis H, Sperr WR, Herndlhofer S, Semper H, Pirc-Danoewinata H, Haas OA et al. Clinical and prognostic significance of histamine monitoring in patients with CML during treatment with imatinib (STI571). Ann Oncol 2007 18 : 1834 1841.
49. Valent P, Agis H, Sperr W, Sillaber C, Horny HP. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia. Leuk Lymphoma 2008 49 : 635 638.
50. Büsche G, Ganser A, Schlegelberger B, von Neuhoff N, Gadzicki D, Hecker H et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia 2007 21 : 2420 2427.
51. Primo D, Tabernero MD, Rasillo A, Sayagués JM, Espinosa AB, Chillón MC et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia 2003 17 : 1124 1129.
52. Douet-Guilbert N, Morel F, Quemener S, Maguer A, Le Bris MJ, Morice P et al. Deletion size characterization of der(9) deletions in Philadelphia-positive chronic myeloid leukemia. Cancer Genet Cytogenet 2006 170 : 89 92.
53. Babicka L, Zemanova Z, Pavlistova L, Brezinova J, Ransdorfova S, Houskova L et al. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2005 168 : 22 9.
54. Krulik M, Smadja N, de Gramont A, Gonzalez-Canali G, Audebert AA, Dray C et al. Sequential karyotype study on Ph-positive chronic myelocytic leukemia. Significance of additional chromosomal abnormalities during disease evolution. Cancer 1987 60 : 974 979.
55. Farag SS, Ruppert AS, Mrózek K, Carroll AJ, Pettenati MJ, Le Beau MM et al. Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. Int J Oncol 2004 25 : 143 151.
56. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells. Cancer 2007 110 : 1509 1519.
57. Hochhaus A, Weisser A, La Rosée P, Emig M, Müller MC, Saussele S et al. Detection and quantification of residual disease in chronic myelogenous leukemia. Leukemia 2000 14 : 998 1005.
58. Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003 17 : 2392 2400.
59. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006 108 : 28 37.
60. Cea M, Cagnetta A, Garuti A, Cirmena G, Rocco I, Moran E et al. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. J Buon 2009 14 : 565 573.
61. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984 63 : 789 799.
62. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998 90 : 850 858.
63. Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med 1990 88 : 1 8.
64. Hasford J, Pfirrmann M, Hehlmann R, Baccarani M, Guilhot F, Mahon FX et al. Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy. Semin Hematol 2003 40 : 4 12.
65. Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 22 : 935 942. (Pubitemid 41103606)
66. White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007 110 : 4064 4072.
67. Picard S, Titier K, Etienne G, Teilhet E, Ducint D, Bernard MA et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007 109 : 3496 3499.
68. Larson RA, Druker BJ, Guilhot F, O'Brien SG, Riviere GJ, Krahnke T et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008 111 : 4022 4028.
69. Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood 2009 114 : 4933 4938.
70. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010 28 : 398 404.
71. Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D et al. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy. Haematologica 2004 89 : 49 57.
72. Goldman J. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era. Curr Opin Hematol 2005 12 : 33 9.
73. Martinelli G, Lacobucci I, Soverini S, Cilloni D, Saglio G, Pane F et al. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management. Hematol Oncol 2006 24 : 196 204.
74. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006 20 : 1925 1930.
75. Bao F, Munker R, Lowery C, Martin S, Shi R, Veillon DM et al. Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias. Mol Diagn Ther 2007 11 : 239 245.
76. Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res 2007 13 : 6136 6143.
77. Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008 112 : 3330 3338.
78. Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009 23 : 1957 1963.
79. Gruber FX, Lamark T, Anonli A, Sovershaev MA, Olsen M, Gedde-Dahl T et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia 2005 19 : 2159 2165.
80. Preuner S, Denk D, Frommlet F, Nesslboeck M, Lion T. Quantitative monitoring of cell clones carrying point mutations in the BCR-ABL tyrosine kinase domain by ligation-dependent polymerase chain reaction (LD-PCR). Leukemia 2008 22 : 1956 1961.
81. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 108 : 1809 1820.
82. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009 27 : 6041 6051.
83. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001 293 : 876 880.
84. Roche-Lestienne C, Preudhomme C. Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin Hematol 2003 40 (S2 8 82.
85. von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107). Blood 2006 108 : 1328 1333.
86. Jabbour E, Kantarjian H, Jones D, Talpaz M, Bekele N, O'Brien S et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 2006 20 : 1767 1773. (Pubitemid 44574988)
87. O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 2007 110 : 2242 2249.
88. Laneuville P, DiLea C, Mestan J, Yin O, Manley PW. Comparative in vitro cellular data alone is insufficient to guide choice of BCR-ABL inhibitor to treat imatinib-resistant chronic myeloid leukemia. Haematologica 2009 94 (S2 260 261.
89. Soverini S, Colarossi S, Gnani A, Castagnetti F, Rosti G, Bosi C et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica 2007 92 : 401 404.
90. Jabbour E, Kantarjian HM, Jones D, Reddy N, O'Brien S, Garcia-Manero G et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 2008 112 : 4839 4842.
91. Shah NP, Kasap C, Weier C, Balbas M, Nicoll JM, Bleickardt E et al. Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008 14 : 485 493.
92. Snead JL, O'Hare T, Adrian LT, Eide CA, Lange T, Druker BJ et al. Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood 2009 114 : 3459 3463.
93. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007 110 : 2828 2837.
94. Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007 109 : 2171 2181.
95. Jabbour E, Cortes J, Kantarjian H, Giralt S, Andersson BS, Giles F et al. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007 110 : 340 344.
96. Menzel H, von Bubnoff N, Hochhaus A, Haferlach C, Peschel C, Duyster J. Successful allogeneic stem cell transplantation in second chronic-phase CML induced by the tyrosine kinase inhibitor nilotinib (AMN107) after blast crisis under imatinib. Bone Marrow Transplant 2007 40 : 83 4.
97. Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007 117 : 2562 2569.
98. Cortes J, Jabbour E, Kantarjian H, Yin CC, Shan J, O'Brien S et al. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007 110 : 4005 4011.
99. Barańska M, Lewandowski K, Gniot M, Iwoła M, Lewandowska M, Komarnicki M. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. J Appl Genet 2008 49 : 201 203.
100. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008 17 : 865 878.
101. Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A et al. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform. Wien Klin Wochenschr 2008 120 : 697 709.
102. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008 26 : 3204 3212.
103. Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 2007 109 : 5143 5150. (Pubitemid 46890528)
104. Quintás-Cardama A, Kantarjian H, O'brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007 25 : 3908 3914.
105. Bergeron A, Réa D, Levy V, Picard C, Meignin V, Tamburini J et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007 176 : 814 818.
106. Sillaber C, Herrmann H, Bennett K, Rix U, Baumgartner C, Böhm A et al. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily. Eur J Clin Invest 2009 39 : 1098 1109.
107. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 354 : 2542 2551. (Pubitemid 43882350)
108. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007 110 : 3540 3546.
109. Abruzzese E, Cantonetti M, Morino L, Orlandi G, Tendas A, Del Principe MI et al. CNS and cutaneous involvement in patients with chronic myeloid leukemia treated with imatinib in hematologic complete remission: two case reports. J Clin Oncol 2003 21 : 4256 4258.
110. Bujassoum S, Rifkind J, Lipton JH. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma 2004 45 : 401 403.
111. Rytting ME, Wierda WG. Central nervous system relapse in two patients with chronic myelogenous leukemia in myeloid blastic phase on imatinib mesylate therapy. Leuk Lymphoma 2004 45 : 1623 1626.
112. Matsuda M, Morita Y, Shimada T, Miyatake J, Hirase C, Tanaka M et al. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate. Int J Hematol 2005 81 : 307 309.
113. Kim HJ, Jung CW, Kim K, Ahn JS, Kim WS, Park K et al. Isolated blast crisis in CNS in a patient with chronic myelogenous leukaemia maintaining major cytogenetic response after imatinib. J Clin Oncol 2006 24 : 4028 4029.
114. Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W et al. Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest 2007 37 : 808 813.
115. Petzer AL, Gunsilius E, Hayes M, Stockhammer G, Duba HC, Schneller F et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. Br J Haematol 2002 117 : 623 625.
116. Takayama N, Sato N, O'Brien SG, Ikeda Y, Okamoto S. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002 119 : 106 108.
117. Wolff NC, Richardson JA, Egorin M, Ilaria RL. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 2003 101 : 5010 5013.
118. Porkka K, Koskenvesa P, Lundan T, Rimpilainen J, Mustjoki S, Smykla R et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008 112 : 1005 1012.
119. Andersen MK, Pedersen-Bjergaard J, Kjeldsen L, Dufva IH, Brøndum-Nielsen K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002 16 : 1390 1393.
120. Meeus P, Demuynck H, Martiat P, Michaux L, Wouters E, Hagemeijer A. Sustained, clonal karyotype abnormalities in the Philadelphia chromosome negative cells of CML patients successfully treated with Imatinib. Leukemia 2003 17 : 465 467.
121. Medina J, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Giles F et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003 98 : 1905 1911. (Pubitemid 37310233)
122. Bumm T, Müller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003 101 : 1941 1949.
123. Terre C, Eclache V, Rousselot P, Imbert M, Charrin C, Gervais C et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004 18 : 1340 1346.
124. Lin Y, Bruyère H, Horsman DE, Pantzar T, Barnett MJ, Hogge DE et al. Philadelphia-negative clonal hematopoiesis following imatinib therapy in patients with chronic myeloid leukemia: a report of nine cases and analysis of predictive factors. Cancer Genet Cytogenet 2006 170 : 16 23.
125. Fabarius A, Haferlach C, Müller MC, Erben P, Lahaye T, Giehl M et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 2007 92 : 834 837.
126. Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006 107 : 752 759.
127. Valent P, Sillaber C, Baghestanian M, Bankl HC, Kiener HP, Lechner K et al. What have mast cells to do with edema formation, the consecutive repair and fibrinolysis? Int Arch Allergy Immunol 1998 115 : 2 8.
128. Sillaber C, Baghestanian M, Bevec D, Willheim M, Agis H, Kapiotis S et al. The mast cell as site of tissue-type plasminogen activator expression and fibrinolysis. J Immunol 1999 162 : 1032 1041.
129. Valent P, Baghestanian M, Bankl HC, Sillaber C, Sperr WR, Wojta J et al. New aspects in thrombosis research: possible role of mast cells as profibrinolytic and antithrombotic cells. Thromb Haemost 2002 87 : 786 790.
130. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008 111 : 1366 1377.
131. Weichsel R, Dix C, Wooldridge L, Clement M, Fenton-May A, Sewell AK et al. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin Cancer Res 2008 14 : 2484 2491.
132. Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood 2008 111 : 3097 3107.
133. Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A 2007 104 : 13283 13288.
134. Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007 110 : 4055 4063.
135. Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007 25 : 1035 1044.
136. La Rosee P, Leitner A, Martiat P, Klag T, Shazi S, Treschl A et al. Weekend holiday from dasatinib in CML patients not tolerating standard dosing regimens: reduced toxicity with maintained disease control. Blood 2009 114 : 459.
137. O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW et al. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res 2005 11 : 6987 6993.
138. Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood 2007 109 : 2112 2120.
139. Quintás-Cardama A, Kantarjian H, Cortes J. Imatinib and beyond - exploring the full potential of targeted therapy for CML. Nat Rev Clin Oncol 2009 6 : 535 543.
140. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009 16 : 401 412.
141. Keller G, Schafhausen P, Brümmendorf TH. Bosutinib. Recent Results Cancer Res 2010 184 : 119 127.
142. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010 28 : 1429 1435.
143. Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G et al. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive Chronic Myeloid Leukemia patients in early chronic phase. Haematologica 2010 in press.
144. Vardiman JW, Melo JV, Baccarani M, Thiele J. Chronic myelogenous leukaemia, BCR/ABL1 positive. In : Swerdlow H et al., editors. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, vol 2. Lyon, France : IARC Press 2008, pp 32 7.
145. Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P, Marega M et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009 27 : 469 471.
146. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia 2010 24 : 6 12.